Sigyn Therapeutics, Inc.
Income Statement
| Line Item | FY2019 | FY2018 | FY2017 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Revenue | $143.3K | $28.3K | $38.4K | $29.2K | $43.2K |
| Cost of Revenue | $35.7K | $9.7K | $21.4K | $9.9K | $25.3K |
| Gross Profit | $107.7K | $18.6K | $17.0K | $19.3K | $17.9K |
| Gross Margin | 75.1% | 65.7% | 44.2% | 66.0% | 41.5% |
| Operating Expenses | |||||
| Research & Development | — | — | — | — | — |
| SG&A Expense | $613.8K | $862.4K | $1.1M | $833.5K | $399.9K |
| Operating Income | $-518.0K | $-1.0M | $-2.0M | $-2.3M | $-387.5K |
| Operating Margin | -361.4% | -3,544.2% | -5,277.4% | -7,714.3% | -898.0% |
| Interest Expense | $55.2K | $352.8K | $790.8K | $-441.2K | — |
| Pretax Income | $-3.3M | $-2.3M | $-3.8M | $-2.7M | $-387.5K |
| Income Tax Expense | — | $800 | $800 | — | — |
| Net Income | $-3.1M | $-2.6M | $-4.3M | $-2.7M | $-387.5K |
| Net Margin | -2,145.3% | -9,243.2% | -11,061.2% | -9,224.9% | -898.0% |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $0.00 |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $0.00 |
| Shares Outstanding (Basic) | 406.4M | 325.3M | 235.5M | 155.0M | 139.8M |
| Shares Outstanding (Diluted) | 406.4M | 325.3M | 235.5M | 155.0M | 139.8M |
| Dividends Per Share | — | — | — | — | — |